Table 2 Compliance and adverse reactions of radiotherapy and chemotherapy.
Characteristics | Neoadjuvant chemotherapy paradigm | P value | ||
|---|---|---|---|---|
IC (n = 16) | CC (n = 20) | IC + CC (n = 26) | ||
Neoadjuvant chemotherapy(mFOLFOX6) cycles | 0.747 | |||
> 1 to ≤ 4 | 7 (43.75) | 7 (35.00) | 8 (30.77) | |
> 4 to ≤ 6 | 9 (56.25) | 13 (65.00) | 18 (69.23) | |
Adjuvant Chemotherapy cycles | 0.531 | |||
0 | 0 (0.00) | 2 (10.00) | 2 (7.69) | |
> 1 to ≤ 4 | 9 (56.25) | 11 (55.00) | 18 (69.23) | |
> 4 to ≤ 6 | 7 (43.75) | 7 (35.00) | 6 (23.08) | |
Radiotherapy and chemotherapy toxicity grade | 0.662 | |||
Gastrointestinal toxicity | ||||
0–1 | 13 (81.25) | 15 (75.00) | 18 (69.23) | |
2–3 | 3 (18.75) | 5 (25.00) | 8 (30.77) | |
Hematologic toxicity | 0.323 | |||
0–1 | 14 (87.50) | 14 (70.00) | 17 (65.38) | |
2–3 | 2 (12.50) | 6 (30.00) | 9 (34.62) | |
Liver function impairment | 0.879 | |||
0–1 | 15 (93.75) | 17 (85.00) | 23 (88.46) | |
2–3 | 1 (6.25) | 3 (15.00) | 3 (11.54) | |
Peripheral neurotoxicity | 0.911 | |||
0–1 | 14 (87.50) | 17 (85.00) | 21 (80.77) | |
2–3 | 2 (12.50) | 3 (15.00) | 5 (19.23) | |
Skin toxicity | 0.895 | |||
0–1 | 14 (87.50) | 18 (90.00) | 22 (84.62) | |
2–3 | 2 (12.50) | 2 (10.00) | 4 (15.38) | |
